

Applicant : Jonathan S. Duke-Cohan et al.
Serial No. : 09/787,097
Filed : March 13, 2001
Page : 2

Attorney's Docket No. 00530-089002

Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims

1. (Cancelled)
2. (Previously presented) An isolated DNA comprising a nucleic acid sequence that encodes an amino acid sequence comprising SEQ ID NO:12.
3. (Previously presented) An isolated DNA comprising a nucleic acid sequence consisting of SEQ ID NO:13.
- 4.- 5. (Cancelled)
6. (Currently amended) An isolated nucleic acid ~~that encodes a fusion protein, the nucleic acid~~ comprising a nucleic acid sequence encoding a fusion protein, the fusion protein consisting of:
 - (a) ~~(i) a nucleotide sequence that encodes SEQ ID NO:12 or (ii) a segment of SEQ ID NO:13 that is at least fifteen nucleotides long, the segment encoding an antigenic fragment of~~ SEQ ID NO:12, wherein the antigenic fragment is at least five amino acids long; and
 - (b) ~~a sequence encoding~~ a heterologous polypeptide.
7. - 19. (Cancelled)
20. (Previously presented) A vector comprising the isolated DNA of claim 2.

Applicant : Jonathan S. Duke-Cohan et al.
Serial No. : 09/787,097
Filed : March 13, 2001
Page : 3

Attorney's Docket No. 00530-089002

21. (Previously presented) The vector of claim 20, wherein the nucleic acid sequence is operably linked to a regulatory element that allows expression of said nucleic acid sequence in a cell.

22. (Previously presented) An isolated cell comprising the vector of claim 21.

23. (Previously presented) A method of producing a polypeptide, the method comprising culturing the cell of claim 22 and purifying the polypeptide from the cell.

24. (Previously presented) A vector comprising the isolated nucleic acid of claim 6.

25. (Previously presented) The vector of claim 24, wherein the nucleic acid is operably linked to a regulatory element that allows expression of said nucleic acid in a cell.

26. (Previously presented) An isolated cell comprising the vector of claim 24.

27. (Previously presented) A method of producing a fusion protein, the method comprising culturing the cell of claim 26 and purifying the fusion protein from the cell.

28. - 37. (Cancelled)

38. (Previously presented) An isolated DNA comprising:

(a) a nucleic acid sequence that (i) encodes a polypeptide that enhances spreading of a macrophage or a monocyte and (ii) hybridizes to the complement of SEQ ID NO:13 under the following conditions: hybridization in 6 X SSC at 30°C, followed by one or more washes in 0.2 X SSC and 0.1% sodium dodecyl sulfate (SDS) at 50°C to 65°C, wherein the nucleic acid sequence consists of SEQ ID NO:1; or

(b) the complement of the nucleic acid sequence.

Applicant : Jonathan S. Duke-Cohan et al.
Serial No. : 09/787,097
Filed : March 13, 2001
Page : 4

Attorney's Docket No. 00530-089002

39. (Previously presented) An isolated DNA comprising:

(a) a nucleic acid sequence that (i) encodes a polypeptide that enhances spreading of a macrophage or a monocyte and (ii) hybridizes to the complement of SEQ ID NO:13 under the following conditions: hybridization in 6 X SSC at 30°C, followed by one or more washes in 0.2 X SSC and 0.1% sodium dodecyl sulfate (SDS) at 50°C to 65°C, wherein the nucleic acid sequence consists of SEQ ID NO:11; or

(b) the complement of the nucleic acid sequence.

40. (Previously presented) An isolated DNA comprising:

(a) a nucleic acid sequence that (i) encodes a polypeptide that enhances spreading of a macrophage or a monocyte and (ii) hybridizes to the complement of SEQ ID NO:13 under the following conditions: hybridization in 6 X SSC at 30°C, followed by one or more washes in 0.2 X SSC and 0.1% sodium dodecyl sulfate (SDS) at 50°C to 65°C, wherein the nucleic acid sequence consists of SEQ ID NO:19; or

(b) the complement of the nucleic acid sequence.

41. - 45. (Cancelled)

46. (Previously presented) The isolated nucleic acid of claim 6, wherein the heterologous polypeptide comprises a signal peptide, a reporter polypeptide, or an immunoglobulin constant region.

47. (Currently amended) An isolated DNA consisting of a ~~segment of SEQ ID NO:13~~ that is at least fifteen nucleotides long, wherein the segment encodes sequence encoding an antigenic fragment of SEQ ID NO:12, wherein the antigenic fragment is at least five amino acids long.

Applicant : Jonathan S. Duke-Cohan et al.
Serial No. : 09/787,097
Filed : March 13, 2001
Page : 5

Attorney's Docket No. 00530-089002

48. (Cancelled).

49. (Previously presented) An isolated DNA comprising a nucleic acid sequence that encodes a polypeptide consisting of the following segments in contiguous order, starting from the N-terminus of the amino acid sequence:

- (a) amino acids 1-30 of SEQ ID NO:12;
- (b) amino acids 31-104 of SEQ ID NO:12;
- (c) amino acids 105-1267 of SEQ ID NO:12; and
- (d) amino acids 1268-1429 of SEQ ID NO:12 or amino acids 1194-1999 of SEQ ID

NO:2,

wherein the polypeptide enhances spreading of a macrophage or a monocyte.

50. (Previously presented) The DNA of claim 49, wherein the polypeptide comprises amino acids 1194-1999 of SEQ ID NO:2.

51. (Previously presented) The DNA of claim 49, wherein the polypeptide comprises amino acids 1268-1429 of SEQ ID NO:12.

52. – 56. (Cancelled)

57. (Previously presented) A vector comprising the isolated DNA of claim 47.

58. (Previously presented) The vector of claim 57, wherein the nucleic acid sequence is operably linked to a regulatory element that allows expression of the nucleic acid sequence in a cell.

59. (Previously presented) An isolated cell comprising the vector of claim 58.

Applicant : Jonathan S. Duke-Cohan et al.
Serial No. : 09/787,097
Filed : March 13, 2001
Page : 6

Attorney's Docket No. 00530-089002

60. (Previously presented) A method of producing a polypeptide, the method comprising culturing the cell of claim 59 and purifying the polypeptide from the cell.

61. (Previously presented) A vector comprising the isolated DNA of claim 49.

62. (Previously presented) The vector of claim 61, wherein the nucleic acid sequence is operably linked to a regulatory element that allows expression of the nucleic acid sequence in a cell.

63. (Previously presented) An isolated cell comprising the vector of claim 62.

64. (Previously presented) A method of producing a polypeptide, the method comprising culturing the cell of claim 63 and purifying the polypeptide from the cell.

65. (Currently amended) The nucleic acid of claim 6, wherein [[the segment]] a nucleotide sequence encoding the antigenic fragment is at least 50 nucleotides long.

66. (Currently amended) The nucleic acid of claim [[6]] 65, wherein the [[segment]] nucleotide sequence is at least 100 nucleotides long.

67. (Currently amended) The nucleic acid of claim [[6]] 65, wherein the [[segment]] nucleotide sequence is at least 300 nucleotides long.

68. (Currently amended) The nucleic acid of claim [[6]] 65, wherein the [[segment]] nucleotide sequence is at least 800 nucleotides long.

Applicant : Jonathan S. Duke-Cohan et al.
Serial No. : 09/787,097
Filed : March 13, 2001
Page : 7

Attorney's Docket No. 00530-089002

69. (Currently amended) The nucleic acid of claim [[6]] 65, wherein the [[segment]] nucleotide sequence is at least 1,500 nucleotides long.

70. (Currently amended) The nucleic acid of claim [[6]] 65, wherein the [[segment]] nucleotide sequence is at least 3,000 nucleotides long.

71. (Currently amended) The nucleic acid of claim [[6]] 65, wherein the [[segment]] nucleotide sequence is at least 4,000 nucleotides long.

72. (Currently amended) The DNA of claim 47, wherein [[the segment]] a nucleotide sequence encoding the antigenic fragment is at least 50 nucleotides long.

73. (Currently amended) The DNA of claim [[47]] 72, wherein the [[segment]] nucleotide sequence is at least 100 nucleotides long.

74. (Currently amended) The DNA of claim [[47]] 72, wherein the [[segment]] nucleotide sequence is at least 300 nucleotides long.

75. (Currently amended) The DNA of claim [[47]] 72, wherein the [[segment]] nucleotide sequence is at least 800 nucleotides long.

76. (Currently amended) The DNA of claim [[47]] 72, wherein the [[segment]] nucleotide sequence is at least 1,500 nucleotides long.

77. (Currently amended) The DNA of claim [[47]] 72, wherein the [[segment]] nucleotide sequence is at least 3,000 nucleotides long.

Applicant : Jonathan S. Duke-Cohan et al.
Serial No. : 09/787,097
Filed : March 13, 2001
Page : 8

Attorney's Docket No. 00530-089002

78. (Currently amended) The DNA of claim [[47]] 72, wherein the [[segment]] nucleotide sequence is at least 4,000 nucleotides long.

79. (Currently amended) An isolated DNA comprising a nucleic acid sequence that encodes a polypeptide consisting of the following segments in contiguous order, starting from the N-terminus of the amino acid sequence:

- (a) amino acids 1-30 of SEQ ID NO:12;
- (b) amino acids 105-1267 of SEQ ID NO:12; and
- (c) amino acids 1268-1429 of SEQ ID NO:12 or amino acids 1194-1999 of SEQ ID

NO:2,

wherein the polypeptide enhances spreading of a macrophage or a monocyte.

80. (Previously presented) A vector comprising the isolated DNA of claim 79.

81. (Previously presented) The vector of claim 80, wherein the nucleic acid sequence is operably linked to a regulatory element that allows expression of the nucleic acid sequence in a cell.

82. (Previously presented) An isolated cell comprising the vector of claim 81.

83. (Previously presented) A method of producing a polypeptide, the method comprising culturing the cell of claim 82 and purifying the polypeptide from the cell.